1 3 700% H		Approved for use through 0	
* /	U.S. Patent no persons are required to respond to a collection	and Trademark Office; U.S. DEPA	
MADER	Application Number	10/659,664	Tallo Omo control names.
TRANSMITTAL	Filing Date	Sept. 10, 2003	
FORM ·	First Named Inventor	Alfred Binggeli	
(to be used for all correspondence after initial fi	(ling) Art Unit	1626	
(10.50.000.00.000.000.000.000.000.000.000	Examiner Name		
Total Number of Pages in This Submission	Attorney Docket Number	21322	
	ENCLOSURES (Check all that	apply)	
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks Cited Art Statement under	to Group Appeal Commu of Appeals and Appeal Commu (Appeal Notice, Proprietary Info Status Letter Other Enclosur Identify below):	unication to Group Brief, Reply Brief) ormation re(s) (please
SIGNAT	TURE OF APPLICANT, ATTORNE	Y, OR AGENT	
Firm or Individual name Eileen M. Ebel			
Signature Sulva Mu			
Date May 11, 2004			
	RTIFICATE OF TRANSMISSION/	MAILING	
I hereby certify that this correspondence is be sufficient postage as first class mail in an env the date shown below.	eing facsimile transmitted to the USPTO or celope addressed to: Commissioner for Pate	deposited with the United State ints, P.O. Box 1450, Alexandri	es Postal Service with ia, VA 22313-1450 on
Typed or printed name Eileen M. E	Ebel		
Signature	WEL.	Date	May 11, 2004
This collection of information is required by 37 CFR	1.5. The information is required to obtain or retain	a benefit by the public which is to	file (and by the USPTO to

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT APPLICATION



e Patent Application

Binggeli et al

Group:

1626

Serial No. 10/659,664, filed Sept. 10, 2003

Examiner:

For: INDOLYL DERIVATIVES

STATEMENT UNDER 37 CFR §1.97(e)

Nutley, New Jersey 07110 May 11, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify:

X That each item of information contained in the enclosed information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this information disclosure statement.

That <u>no</u> item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Attorney for Applicant(s)

Eileen M. Ebel (Reg. No. 37316) 340 Kingsland Street

Nutley, NJ 07110

Telephone: (973) 235-4391 Telefax: (973) 235-2363

142012



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Blnggeli et al

Group: 21322

Serial No. 10/659,664, filed Sept. 10, 2003

Examiner:

For: INDOLYL DERIVATIVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 May 11, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A10-A11, B21-B24, C26-C27 are listed on Form PTO-1449. Documents B21-B24, C26-C27 are enclosed

Enclosed is a Search Report, dated February 13, 2004, which was issued by the European Patent Office in the PCT/ EP 03/09819 application corresponding to the captioned application. The Search Report lists Documents A10-A11, B21-B24, C26-C27.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/659,664

Filed: Sept. 10, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits and/or because each item of information contained in the Information Disclosure Statement was cited in a communication for the first time from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Eileen M. Ebel (Reg. No. 37316) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4391

Telefax: (973) 235-2363

142004

إيبر 2004		Substitute for form 1449A/PTO			Comple	ete if Kno	wn	
TOOL STATE	ORMA	ATION	DISCLOSUI APPLICAI if necessary)	RE	Application Number			
T	ATEMI	ENT BY	APPLICA	TV	Filing Date	iling Date Sept. 10,		
DEMAR					First Name Inventor	Alfred B	ingelli	
	(Use sev	eral sheets	if necessary)		Group Art Unit	1626		
					Examiner Name			
Sheet 1		of	2		Attorney Docket Number	21322		
				U.S. PATI	ENT DOCUMENTS			
		U.S	S. Patent Docu	ment				
Examiner Initials'		No.' Number	Kind Code ²		Name of Patentee or Appl Cited Document	licant of	cant of Date of Publicati	
initials	No.'		r	(if known)	Cited Document	MM-DD-Y		
	A10	5 811	439		Ogawa Masashi et al		09-22-1998	
	A11	6,069	,156		Oku et al		05-30-2000	
				-	<u> </u>			
				1				
		-						
		ļ		 			<u> </u>	
				į.				
	·							
		I	FC	REIGN PA	ATENT DOCUMENTS		l	
Foreign Patent Document							e of Publication of	Т°

Examiner	Cite	Foreign	Patent Docum	ent	Name of Patentee or	Date of Publication of Cited Document	Т°
Initials'	No.'	Office ³	Number	Kind Code ⁵ (if known)	Applicant of Cited Document	MM-DD-YYYY	
-	B21	WO 9	6 26207		Nissan Chemical Ind	08-29-1996	
					Ltd		
	B22	WO 0	2 08188		Merck & Co. Inc.	01-31-2002	
	B23	WO 9	7 27857		Bergman et al	08-07-1997	
	B24	WO 0	3 040114		Bristol Myers Co	05-15-2003	
Examiner Signature		Date Co	nsidered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO				Complete if Known		
I	NFORMA	ATION	DISCLOSURE	Application Number	10/659,664	
	STATEMENT BY APPLICANT			Filing Date	Sept. 10, 2003	
(Use several sheets if necessary)				First Name Inventor	Alfred Bingelli	
			ets if necessary)	Group Art Unit	1626	
				Examiner Name		
Sheet	2	Of	2	Attorney Docket Number	21322	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-	T ²
initials		issue number(s), publisher, city and/or country where published	
	C26	OKU, TERUO ET, Database CA, Abstract XP002265626	<u> </u>
	C27	HENKE B R ET AL, Bioorganic & Medicinal Chemistry	
		Letters, Vol 9 (23) (Dec. 1999)	
•			
·			
-			
	1		
Examiner Signature	1	DATE CONSIDERED	L

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

142006